ENDOGENOUS RESTORATION OF NORADRENALINE BY PRECURSOR THERAPY IN DOPAMINE-BETA-HYDROXYLASE DEFICIENCY

@article{Biaggioni1987ENDOGENOUSRO,
  title={ENDOGENOUS RESTORATION OF NORADRENALINE BY PRECURSOR THERAPY IN DOPAMINE-BETA-HYDROXYLASE DEFICIENCY},
  author={I. Biaggioni and D. Robertson},
  journal={The Lancet},
  year={1987},
  volume={330},
  pages={1170-1172}
}
  • I. Biaggioni, D. Robertson
  • Published 1987
  • Medicine
  • The Lancet
  • DL-dihydroxyphenylserine was given by mouth in a single-blind, placebo-controlled trial to two patients with orthostatic hypotension due to dopamine-beta-hydroxylase deficiency, in the hope of providing noradrenaline by endogenous decarboxylation. Dose-dependent increases in blood pressure were obtained over the range 150-600 mg. After 600 mg mean arterial pressure rose 33 and 19 mm Hg and these rises were tightly correlated with an increase in plasma noradrenaline (r = 0.995, p less than 0.001… CONTINUE READING
    103 Citations
    L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension
    • 58
    Attenuation of haloperidol-induced catalepsy by noradrenaline and L-threo-DOPS
    • 11
    The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors.
    • H. Kaufmann
    • Biology, Medicine
    • Journal of neural transmission. Supplementum
    • 2006
    • 10
    Dopamine beta-hydroxylase deficiency
    • 52
    • PDF
    Droxidopa (L-DOPS)
    Double-Blind , Placebo-Controlled , Crossover Study
    • 54

    References

    SHOWING 1-10 OF 15 REFERENCES
    Pressor effect of L‐threo‐3,4‐dihydroxyphenylserine in rats
    • 28